One of the latest elaborations of biotechnological group Alkor Bio – reagents kits “Cystic Fibrosis-BioChip”, aimed for molecular-genetic diagnostics of Cystic Fibrosis, got the registration certificate of Federal Service on Surveillance in Healthcare and Social Development of Russian Federation.

Cystic fibrosis (CF) is one of the most common autosomal recessive diseases caused by mutations in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene which lead to malfunction of the protein. An abnormal CFTR protein results in defective electrolyte transport and defective chloride ion transport in the apical membrane epithelial cells of the sweat gland, lung, pancreas, and intestine.

It is important to mention that nowadays doctors in Russia stand for the transfer of diagnostic scheme of the disease. Following the latest trends of organization of neonatal screening Saint-Petersburg biotechnical company Alkor Bio developed “Cystic Fibrosis-BioChip” to give specialists the ability to perform the molecular-genetic diagnostics on the earlier stages of the scheme. Moreover, the diagnostic kit was developed specifically for detection of mutations that are found at high frequency in Slavic population which makes it perfect for use in Russia. Another advantage of the test is that DNA for the analysis can be obtained from samples of dry blood spots.